(VIANEWS) – Shares of Xenetic Biosciences (NASDAQ: XBIO) jumped by a staggering 27.32% in 10 sessions from $3.24 at 2023-07-05, to $4.12 at 14:38 EST on Wednesday, after two consecutive sessions in a row of gains. NASDAQ is sliding 0.19% to $14,326.28, after two sequential sessions in a row of gains.
Xenetic Biosciences’s last close was $3.78, 62.2% below its 52-week high of $10.00.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-3.76.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.06%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 55.7%, now sitting on 1.92M for the twelve trailing months.
Sales Growth
Xenetic Biosciences’s sales growth is 5.5% for the present quarter and 15.9% for the next.
Moving Average
Xenetic Biosciences’s worth is way higher than its 50-day moving average of $3.38 and under its 200-day moving average of $4.32.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 40.5% and a drop 86.7% for the next.
More news about Xenetic Biosciences (XBIO).
